Yizhen Liu

13PUBLICATIONS
17CO-AUTHORS
Haematological tumoursEnvironmental epidemiologyPredictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)Applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (13)

|Jul 01, 2026
Zanubrutinib combined with R-CHOP in previously untreated diffuse large B-cell lymphoma with specific gene alteration: a phase II study.

|Dec 10, 2025
HERVH-derived eRNA activates a super-enhancer-driven ALDH1A3/SAT1 axis to promote ferroptosis escape and pancreatic cancer development.

Lili Yuan, Jiahui Yu, Xiaoli Xu

|Nov 24, 2025
Prognostic Significance of Deubiquitinase OTUD7B in NK/T-Cell Lymphoma.

Yizhen Liu, Shujuan Wen, Zuguang Xia

|Feb 25, 2025
Lenalidomide combined with R-CHOP (R2-CHOP) in the treatment of newly diagnosed double-expressor diffuse large B-cell lymphoma: a prospective phase II clinical trial.

Yizhen Liu, Qunling Zhang, Fangfang Lv

|Aug 29, 2024
Chidamide plus R-GDP for relapsed/refractory diffuse large B-cell lymphoma in patients ineligible for autologous transplantation: A prospective, single-arm, phase II study.

Guang-Liang Chen, Kai Xue, Qunling Zhang

|Jul 04, 2024
Transposable elements-mediated recruitment of KDM1A epigenetically silences HNF4A expression to promote hepatocellular carcinoma.

Tiantian Jing, Dianhui Wei, Xiaoli Xu

Pageof 3

Frequent Collaborators

2 joint publications

Dianhui Wei

2 joint publications

Boshi Wang

2 joint publications

Junning Cao

1 joint publications

Pan Luo